An important factor predicting poor prognosis is the amplification of the MYCN gene, which occurs in 30-40% of all high-risk NB tumors; this amplification strongly correlates with advanced-stage disease and treatment failure (2). The gene discussed is MYCN; the disease is neuroblastoma.